Flow Cytometry The Flow Cytometry Core provides services to HCCC members from all 6 research programs conducting both laboratory and clinical cancer research. The mission of the Flow Cytometry Facility is to serve HCCC investigators by providing state-of-the-art Flow Cytometry Services including: 1) High speed sorting 2) Multi-parameter analysis 3) High efficiency purification of cell subsets 4) Training and assisting investigators with software programs available for interpretation and analysis of data 5) Individual training of the investigators and their laboratory personnel in the use of the bench-top instruments, which are subsequently available to them on a 24/7 basis. The Flow Cytometry Facility is in a constant process of developing new technology and services as requested and/or needed by HCCC investigators. Consultation is readily available to all investigators by the Director, the Technical Director and other support personnel in the facility. In 2009, 72 HCCC members with peer-reviewed research funding used the Flow Cytometry Facility.
The ability to analyze the expression of molecules on the surface and within individual cells, and to sort those cells based on expression of those molecules, is an essential tool for many cancer investigators. The cancer research supported by this shared resource provides state-of-the-art facilities and outstanding expertise in Flow Cytometry and cell sorting.
|Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312|
|Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30|
|Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667|
|Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149|
|Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332|
|Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487|
|Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636|
|Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :|
|Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165|
|Borcherding, Nicholas; Kolb, Ryan; Gullicksrud, Jodi et al. (2018) Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 430:2014-2029|
Showing the most recent 10 out of 1080 publications